NHS to offer life-changing' gene therapy for blood disorder thalassaemia
Briefly

Casgevy gene therapy approved for severe thalassaemia on NHS in England, offering potential cure with benefits for patients.
Casgevy works by editing a gene in bone marrow to produce functioning haemoglobin; 93% in trials did not need transfusion for a year.
Amanda Pritchard: Revolutionary moment for thalassaemia patients with quality of life impact, hope for longer life; latest in NHS gene therapies brings significant benefits.
Read at www.theguardian.com
[
|
]